BRAF and colorectal cancer: We conducted an early post-marketing phase vigilance (EPPV) study to collect reports of adverse drug reactions (ADRs) during the first 6 months after the approval of the triplet and doublet regimens for BRAF V600E-mutated colorectal cancer.